S&P 500   3,312.99 (-0.08%)
DOW   27,345.53 (+0.21%)
QQQ   271.35 (-0.41%)
AAPL   111.61 (-0.18%)
MSFT   205.90 (-0.73%)
FB   256.77 (+0.79%)
GOOGL   1,447.78 (-0.82%)
AMZN   3,087.48 (-1.33%)
NVDA   506.55 (+0.21%)
TSLA   402.59 (-5.10%)
BABA   277.68 (+0.87%)
CGC   15.56 (-2.99%)
GE   6.36 (+1.76%)
MU   51.17 (+2.96%)
AMD   77.56 (-0.18%)
T   28.54 (+0.11%)
F   6.88 (+1.47%)
ACB   5.72 (-21.86%)
GILD   63.71 (+0.49%)
NFLX   487.35 (-0.78%)
DIS   126.91 (-0.24%)
BAC   24.15 (+0.88%)
BA   159.34 (+1.62%)
S&P 500   3,312.99 (-0.08%)
DOW   27,345.53 (+0.21%)
QQQ   271.35 (-0.41%)
AAPL   111.61 (-0.18%)
MSFT   205.90 (-0.73%)
FB   256.77 (+0.79%)
GOOGL   1,447.78 (-0.82%)
AMZN   3,087.48 (-1.33%)
NVDA   506.55 (+0.21%)
TSLA   402.59 (-5.10%)
BABA   277.68 (+0.87%)
CGC   15.56 (-2.99%)
GE   6.36 (+1.76%)
MU   51.17 (+2.96%)
AMD   77.56 (-0.18%)
T   28.54 (+0.11%)
F   6.88 (+1.47%)
ACB   5.72 (-21.86%)
GILD   63.71 (+0.49%)
NFLX   487.35 (-0.78%)
DIS   126.91 (-0.24%)
BAC   24.15 (+0.88%)
BA   159.34 (+1.62%)
S&P 500   3,312.99 (-0.08%)
DOW   27,345.53 (+0.21%)
QQQ   271.35 (-0.41%)
AAPL   111.61 (-0.18%)
MSFT   205.90 (-0.73%)
FB   256.77 (+0.79%)
GOOGL   1,447.78 (-0.82%)
AMZN   3,087.48 (-1.33%)
NVDA   506.55 (+0.21%)
TSLA   402.59 (-5.10%)
BABA   277.68 (+0.87%)
CGC   15.56 (-2.99%)
GE   6.36 (+1.76%)
MU   51.17 (+2.96%)
AMD   77.56 (-0.18%)
T   28.54 (+0.11%)
F   6.88 (+1.47%)
ACB   5.72 (-21.86%)
GILD   63.71 (+0.49%)
NFLX   487.35 (-0.78%)
DIS   126.91 (-0.24%)
BAC   24.15 (+0.88%)
BA   159.34 (+1.62%)
S&P 500   3,312.99 (-0.08%)
DOW   27,345.53 (+0.21%)
QQQ   271.35 (-0.41%)
AAPL   111.61 (-0.18%)
MSFT   205.90 (-0.73%)
FB   256.77 (+0.79%)
GOOGL   1,447.78 (-0.82%)
AMZN   3,087.48 (-1.33%)
NVDA   506.55 (+0.21%)
TSLA   402.59 (-5.10%)
BABA   277.68 (+0.87%)
CGC   15.56 (-2.99%)
GE   6.36 (+1.76%)
MU   51.17 (+2.96%)
AMD   77.56 (-0.18%)
T   28.54 (+0.11%)
F   6.88 (+1.47%)
ACB   5.72 (-21.86%)
GILD   63.71 (+0.49%)
NFLX   487.35 (-0.78%)
DIS   126.91 (-0.24%)
BAC   24.15 (+0.88%)
BA   159.34 (+1.62%)
Log in
NYSE:MRK

Merck & Co., Inc. Stock Forecast, Price & News

$83.10
+0.16 (+0.19 %)
(As of 09/23/2020 09:51 AM ET)
Add
Compare
Today's Range
$82.82
Now: $83.10
$83.36
50-Day Range
$80.91
MA: $84.15
$86.93
52-Week Range
$65.25
Now: $83.10
$92.64
Volume37,495 shs
Average Volume10.95 million shs
Market Capitalization$210.18 billion
P/E Ratio20.27
Dividend Yield2.94%
Beta0.45
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; and Eisai Co., Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Read More
Merck & Co., Inc. logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.93 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP58933Y10
Phone908-740-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.84 billion
Cash Flow$6.61 per share
Book Value$10.21 per share

Profitability

Net Income$9.84 billion

Miscellaneous

Employees71,000
Outstanding Shares2,529,241,000
Market Cap$210.18 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$83.10
+0.16 (+0.19 %)
(As of 09/23/2020 09:51 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

How has Merck & Co., Inc.'s stock been impacted by Coronavirus?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRK stock has increased by 4.9% and is now trading at $83.10.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Merck & Co., Inc.?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc.
.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Merck & Co., Inc.
.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings results on Friday, July, 31st. The company reported $1.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.14 by $0.23. The company earned $10.87 billion during the quarter, compared to analyst estimates of $10.52 billion. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The firm's revenue for the quarter was down 7.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.30 EPS.
View Merck & Co., Inc.'s earnings history
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Wednesday, July 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 annualized dividend and a yield of 2.94%. The ex-dividend date of this dividend is Monday, September 14th.
View Merck & Co., Inc.'s dividend history
.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. declared that its board has authorized a stock buyback program on Thursday, October 25th 2018, which permits the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 5.1% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY20 earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

What price target have analysts set for MRK?

13 equities research analysts have issued twelve-month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $94.54 in the next year. This suggests a possible upside of 13.8% from the stock's current price.
View analysts' price targets for Merck & Co., Inc.
.

Has Merck & Co., Inc. been receiving favorable news coverage?

News coverage about MRK stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merck & Co., Inc. earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Merck & Co., Inc.
.

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a decrease in short interest in the month of August. As of August 14th, there was short interest totaling 11,800,000 shares, a decrease of 13.9% from the July 30th total of 13,700,000 shares. Based on an average daily volume of 9,150,000 shares, the short-interest ratio is currently 1.3 days. Currently, 0.5% of the shares of the company are short sold.
View Merck & Co., Inc.'s Short Interest
.

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Home Depot (HD).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:
  • Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 64)
  • Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 52)
  • Ms. Jennifer L. Zachary, Exec. VP & Gen. Counsel (Age 41)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 67)
  • Mr. Adam H. Schechter, Special Advisor (Age 54)

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.41%), BlackRock Inc. (7.81%), Bank of New York Mellon Corp (1.25%), Nordea Investment Management AB (0.73%), FMR LLC (0.51%) and Sumitomo Mitsui Trust Holdings Inc. (0.50%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc.
.

Which institutional investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of New York Mellon Corp, Marshall Wace North America L.P., Toronto Dominion Bank, Bank of Nova Scotia, Thornburg Investment Management Inc., CIBC Private Wealth Group LLC, and Victory Capital Management Inc.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Sanat Chattopadhyay, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc.
.

Which institutional investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Point72 Asset Management L.P., Sarasin & Partners LLP, Epoch Investment Partners Inc., Ceredex Value Advisors LLC, BlackRock Inc., TD Asset Management Inc., and Sumitomo Mitsui Trust Holdings Inc..
View insider buying and selling activity for Merck & Co., Inc.
.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $83.10.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $210.18 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.